LORATADINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H23ClN2O2
Molecular Weight	382.883
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC(=O)N1CCC(CC1)=C2C3=C(CCC4=C2N=CC=C4)C=C(Cl)C=C3

InChI

InChIKey=JCCNYMKQOSZNPW-UHFFFAOYSA-N

InChI=1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3

HIDE SMILES / InChI

Molecular Formula	C22H23ClN2O2
Molecular Weight	382.883
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021952Orig1s012lbl.pdf

Loratadine is a derivative of azatadine and a second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (histamine H1 antagonists) it lacks central nervous system depressing effects such as drowsiness. Loratadine competes with free histamine and exhibits specific, selective peripheral H1 antagonistic activity. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine. Loratadine has low affinity for cholinergic receptors and does not exhibit any appreciable alpha-adrenergic blocking activity in-vitro. Loratadine also appears to suppress the release of histamine and leukotrienes from animal mast cells, and the release of leukotrienes from human lung fragments, although the clinical importance of this is unknown.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H1 receptor 312 Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7581058	Antagonist 2737

Conditions

Condition	Modality	Targets	Highest Phase	Product
Upper respiratory allergies 8 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021952Orig1s012lbl.pdf	Primary		Approved 8307	CLARITIN Approved Use Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: •runny nose •itchy, watery eyes •sneezing •itching of the nose or throat Launch Date 7.3457277E11

C_max

Value	Dose	Analyte	Population
4 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021165s014lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DESLORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
27.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2958516/	40 mg 1 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22806583/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
56.9 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021165s014lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DESLORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
96 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2958516/	40 mg 1 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
34.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22806583/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
27 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021165s014lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DESLORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
14.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2958516/	40 mg 1 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
11 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22806583/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
84.5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021165s014lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DESLORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2572617/	unhealthy, 29 n = 103 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 29 Sex: M+F Population Size: 103 Sources: https://pubmed.ncbi.nlm.nih.gov/2572617/	Other AEs: Somnolence, Headache... Other AEs: Somnolence (10%) Headache (9%) Fatigue (5%) Dry mouth (4%) Sources: https://pubmed.ncbi.nlm.nih.gov/2572617/
5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-641S007_Loratadine_medr.pdf	unhealthy, 3.6 n = 60 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 3.6 Sex: M+F Population Size: 60 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-641S007_Loratadine_medr.pdf	Other AEs: Fatigue, Fever... Other AEs: Fatigue (2%) Fever (7%) Headache (5%) Influenza-like symptoms (2%) Constipation (2%) Diarrhea (3%) Dyspepsia (2%) Loose stools (2%) Stomatitis (2%) Tooth disorder (2%) Vomiting (5%) Earache (2%) Drowsiness (7%) Infection viral (2%) Allergic rhinitis (2%) Coughing (3%) Epistaxis (3%) Pharyngitis (3%) Rash (2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-641S007_Loratadine_medr.pdf
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10929922/	unhealthy, 35.3 n = 331 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 35.3 Sex: M+F Population Size: 331 Sources: https://pubmed.ncbi.nlm.nih.gov/10929922/	Other AEs: Headache... Other AEs: Headache (4.2%) Sources: https://pubmed.ncbi.nlm.nih.gov/10929922/

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1670 inhibitor 1532	substrate 985 inhibitor 1695 activator 21	substrate 1168 inhibitor 1789	inhibitor 1570

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C19 1410 CYP1A2 1463 CYP2C8 869 P-gp 1401	CYP1A1 344 CYP2C19 955 CYP1A2 1013 CYP2B6 648 CYP2C8 670 CYP3A5 383 P-gp 1491	CYP3A1/2 3 CYP2B1 24 CYP2B2 13 CYP1A1 103

Drug as perpetrator

Target	Modality	Activity
CYP1A1 206	inducer 1515 Sources: https://pubmed.ncbi.nlm.nih.gov/1534660/ Page: 1.0	no
CYP1A2 1620	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/11502723/	no
CYP2C9 1747	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/10597902/ Page: 11.0	no
CYP3A4 1857	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/11502723/	no
CYP2D6 1826	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/11502723/	yes [IC50 0.61 uM]
CYP2C19 1484	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/11502723/	yes [IC50 0.76 uM]
P-gp 1588	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/11454724/	yes [IC50 11 uM]
CYP2C8 923	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/15601807/ Page: 6.0	yes [IC50 3.36 uM]
CYP2B1 39	inducer 1515 Sources: https://pubmed.ncbi.nlm.nih.gov/1534660/ Page: 1.0	yes
CYP2B2 14	inducer 1515 Sources: https://pubmed.ncbi.nlm.nih.gov/1534660/ Page: 1.0	yes
CYP2C9 1747	activator 208 Sources: https://pubmed.ncbi.nlm.nih.gov/10597902/ Page: 1,8	yes
CYP3A1/2 4	inducer 1515 Sources: https://pubmed.ncbi.nlm.nih.gov/1534660/ Page: 1.0	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A4 1670	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20641s7lbl.pdf#page=1 Page: 1.0	major	yes (co-administration study) Comment: Coadministration with either ketoconazole, erythromycin (both CYP3A4 inhibitors) increased AUC of drug by 307%, 40%, respectively; coadministration with cimetidine (CYP2D6 and CYP3A4 inhibitor) increased AUC of drug by 103% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20641s7lbl.pdf#page=1 Page: 1.0
CYP1A1 344	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/19702548/	minor
CYP1A2 1013	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/19702548/	minor
CYP2B6 648	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/19702548/	minor
CYP2C19 955	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/19702548/	minor
CYP2C8 670	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/19702548/	minor
CYP2C9 985	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/19702548/	minor
CYP3A5 383	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/19702548/	minor
CYP2D6 1168	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20641s7lbl.pdf#page=1 Page: 1.0	minor	yes (co-administration study) Comment: coadministration with cimetidine (CYP2D6 and CYP3A4 inhibitor) increased AUC of drug by 103% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20641s7lbl.pdf#page=1 Page: 1.0
P-gp 1491	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/12584158/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1603	inhibitor 1584 Sources: https://pubmed.ncbi.nlm.nih.gov/10604956/

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	NO15960	https://www.001chemical.com/chem/79794-75-5
3B Scientific (Wuhan) Corp	3B2-0771	http://www.3bsc.com/index/pro_info.php?id=20127
3B Scientific (Wuhan) Corp	3B1-00337	http://www.3bsc.com/index/pro_info.php?id=20549
AA Blocks	AA00ICZV	https://www.aablocks.com/goods/Goods/detail?id=AA00ICZV
AEchem Scientific Corp., USA	AE1-019802	http://www.aechemsc.com/info_products/AE1-019802.php
AHH Chemical co.,ltd	API-1744	http://www.ahhchemical.com/product/API-1744.html
AK Scientific, Inc. (AKSCI)	71291	http://www.aksci.com/item_detail.php?cat=71291
AK Scientific, Inc. (AKSCI)	HTS028367	http://www.aksci.com/item_detail.php?cat=HTS028367
AK Scientific, Inc. (AKSCI)	J10034	http://www.aksci.com/item_detail.php?cat=J10034
Aaron Chemicals	AR00IDRN	http://www.aaronchem.com/79794-75-5
AbMole Bioscience	M5752	http://www.abmole.com/products/loratadine.html
Accela ChemBio Inc	SY052751	http://www.accelachem.com/cn/search.html?keyword=SY052751&attname=GoodsCode
Achemo Scientific Limited	AC-14832	http://www.achemo.com/product_view.asp?ID=4722
Achemo Scientific Limited	AC-74979	http://www.achemo.com/search/?Keyword= 79794-75-5
Achemtek	0104-001717	http://www.achemtek.com/79794-75-5
Acorn PharmaTech	ACN-048230	http://www.acornpharmatech.com/
Adooq BioScience	A10538	https://www.adooq.com/loratadine.html
Alfa Chemistry	AP79794755	https://reagents.alfa-chemistry.com/product/loratadine-cas-79794-75-5-16699.html
Angene	AGN-PC-0UFD74	http://www.angenechemical.com/productshow/AGN-PC-0UFD74.html
ApexBio Technology	A2960	http://www.apexbt.com/loratadine-22071.html
Ark Pharm	AK-88666	http://www.arkpharminc.com/products/79794-75-5.html
AstaTech, Inc.	34558	http://www.astatechinc.com/CPSResult.php?CRNO=35766
Aurum Pharmatech LLC	M-5196	http://www.Aurumpharmatech.com/Product/ProductDetails/M_5196
AvaChem Scientific	2987	http://www.avachem.com/productSearch.asp?2987
Avantor Inc	100573-700	https://us.vwr.com/store/catalog/product.jsp?catalog_number=100573-700
Axon MedChem	1299	https://www.axonmedchem.com/product/1299
BLD Pharm	BD22650	http://www.bldpharm.com/products/79794-75-5.html
BLD Pharm	BD341540	http://www.bldpharm.com/products/79794-75-5.html
BOC Sciences	1020719-57-6	https://www.bocsci.com/loratadine-d5-cas-1020719-57-6-item-472497.html
BOC Sciences	1398065-63-8	https://www.bocsci.com/loratadine-d5-ethyl-d5-cas-1398065-63-8-item-7891.html
BioChemPartner	BCP22338	http://www.biochempartner.com/79794-75-5-BCP22338
BioCrick	BCC1262	http://www.biocrick.com/Loratadine-BCC1262.html
BioSynth	Q-100833	https://www.biosynth.com/en/products/life-science/other-biochemicals/products/Q-100833.html
CSNpharm	CSN12956	https://www.csnpharm.com/products/loratadine.html
Chem Scene	CS-0887	http://www.chemscene.com/79794-75-5.html
ChemMol	30101835	http://www.chemmol.com/chemmol/30101835.html
ChemMol	44001626	http://www.chemmol.com/chemmol/44001626.html
ChemMol	49408235	http://www.chemmol.com/chemmol/49408235.html
ChemMol	97900024	http://www.chemmol.com/chemmol/97900024.html
ChemReagents	80006240	http://www.chemreagents.com/Product/Product.asp?ProductID=80006240
Chemenu	CM110558	http://www.chemenu.com/products/CM110558
Chemspace	CSSB00000693942	https://chem-space.com/CSSB00000693942
Clearsynth	CS-O-03616	http://www.clearsynth.com/en/CSO03616.html
Clearsynth	CS-O-07780	http://www.clearsynth.com/en/CSO07780.html
Clearsynth	CS-O-01778	https://www.clearsynth.com/en/CSO01778.html
DC Chemicals	DC9104	http://www.dcchemicals.com/product_show-Loratadine.html
Enamine	Z1741979837	https://www.enaminestore.com/catalog/Z1741979837
Finetech	FT-0627976	http://www.finetechnology-ind.com/prod/detail/pub/79794-75-5.html
Glentham Life Sciences	GP7681	http://www.glentham.com/products/product/GP7681/
LGC Standards	LGCAMP0257.00-02	https://www.lgcstandards.com/US/en/p/LGCAMP0257.00-02
LGC Standards	LGCFOR0257.00	https://www.lgcstandards.com/US/en/p/LGCFOR0257.00
LGC Standards	MM0257.00-0250	https://www.lgcstandards.com/US/en/p/MM0257.00-0250
Lab Network	LN00188253	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00188253
Matrix Scientific	89794	https://www.matrixscientific.com/089794.html
MedChem Express	HY-17043	https://www.medchemexpress.com/Loratadine.html
Molcore	CS15960	https://www.molcore.com/product/79794-75-5
OChem	3802	http://www.ocheminc.com/index.php?act=psearch&pid=794L755
Oakwood	214656	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=95655&ExtHyperLink=1
Selleck Chemicals	S1358	http://www.selleckchem.com/products/Loratadine.html
Sigma-Aldrich	BP874_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/bp874?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	PHR1376_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/phr1376?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	Y0000603_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/y0000603?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	L9664_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/l9664?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1370270_USP	https://www.sigmaaldrich.com/catalog/product/usp/1370270?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S533555	http://www.smolecule.com/products/s533555
Synblock Inc	AB06849	http://www.synblock.com/product/79794-75-5.html
TCI (Tokyo Chemical Industry)	L0223	http://www.tcichemicals.com/eshop/en/us/commodity/L0223/index.html
THE BioTek	bt-273709	https://www.thebiotek.com/product/inhibitors/bt-273709
Tocris	1944	https://www.tocris.com/products/loratidine_1944
TripleBond	CL0028	http://www.triplebond-canada.com/prod/1411/
VladaChem	VL272222-1g	https://www.vladachem.com/product.php?products=79794-75-5
Yuhao Chemical	RT4149	http://www.chemyuhao.com/165739-83-3.html
abcr GmbH	AB261650	http://www.abcr.com/shop/en/AB261650
eNovation Chemicals	D378653	https://www.enovationchem.com/ProductDetails.asp?ProductID=D378653
eNovation Chemicals	D488439	https://www.enovationchem.com/ProductDetails.asp?ProductID=D488439
iChemical	EBD53298	http://www.ichemical.com/products/79794-75-5.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
mcule	MCULE-5073177964	https://mcule.com/MCULE-5073177964/

PubMed

Title	Date	PubMed
Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury.	1999 Dec	10628507
Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine.	1999 Dec 15	10529725
Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study.	1999 Jan	10188144
Mechanism responsible for epileptogenic activity by first-generation H1-antagonists in rats.	2000 Dec 22	11134603
Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions.	2000 Jan	10604956
Cetirizine and loratadine: a comparison using the ED50 in skin reactions.	2000 Mar-Apr	10898119
The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare.	2001	11922397
Treatment of urticaria. An evidence-based evaluation of antihistamines.	2001	11702618
The pharmacologic profile of desloratadine: a review.	2001	11243504
Desloratadine: a new approach in the treatment of allergy as a systematic disease--pharmacology and clinical overview. Introduction.	2001	11243503
Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells.	2001 Aug	11496238
Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein.	2001 Aug	11454724
Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study.	2001 Jan	11277962
Triamcinolone: new and old indications.	2001 Jul	11583068
FDA panel recommends OTC status for second-generation antihistamines.	2001 Jul	11476458
Evaluation of quality of life in children and teenagers with allergic rhinitis: adaptation and validation of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ).	2001 Jul-Aug	11674923
An investigation into the effects of cetirizine on cognitive function and psychomotor performance in healthy volunteers.	2001 Mar	11317473
Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow.	2001 Mar	11179434
Children's school performance is not impaired by short-term administration of diphenhydramine or loratadine.	2001 May	11343039
Synergistic antiallergic activity of combined histamine H1- and cysteinyl leukotriene1-receptor blockade in human bronchus.	2001 May 11	11432448
Determination of loratadine in human plasma by high-performance liquid chromatographic method with ultraviolet detection.	2001 May 5	11393721
[Childhood asthma and viral infection: interactions and therapeutic possibilities].	2001 May-Jun	11434888
Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis.	2001 Nov	11703222
Inhibition of depolarization-induced [3H]noradrenaline release from SH-SY5Y human neuroblastoma cells by some second-generation H(1) receptor antagonists through blockade of store-operated Ca(2+) channels (SOCs).	2001 Nov 1	11705456
Variant effect of first- and second-generation antihistamines as clues to their mechanism of action on the sneeze reflex in the common cold.	2001 Nov 1	11588693
Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis.	2001 Nov 26	11718589
Effect of specific immunotherapy versus loratadine on serum adhesion molecules.	2001 Oct	11763722
Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare, and itch in human skin.	2001 Oct	11576078
Do antihistamines impair school performance in children?	2001 Sep	11674900
Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine.	2001 Sep	11591186
Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine.	2002	11978146
Clinical evidence for antileukotriene therapy in the management of allergic rhinitis.	2002 Apr	11991547
A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects.	2002 Feb	11868924
Cardiotoxicity of new antihistamines and cisapride.	2002 Feb 28	12052668
Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis.	2002 Jun	12063523
Which is more effective for as-needed treatment of seasonal allergy symptoms: intranasal corticosteroids or oral antihistamines?	2002 Mar	11978243
A randomized, double-blind, placebo-controlled comparison of emedastine 0.05% ophthalmic solution with loratadine 10 mg and their combination in the human conjunctival allergen challenge model.	2002 Mar	11952027

Patents

Sample Use Guides

In Vivo Use Guide

Adults and children 6 years and over: 1 tablet daily; not more than 1 tablet in 24 hours

Route of Administration: Oral

In Vitro Use Guide

dose-dependent inhibition of histamine release was observed at loratadine dose above 7 UM. In the rat basophilic leukemia cells (RBL-2H3) experimental system, inhibition by loratadine increased when the concentration of extracellular Ca2+ was reduced from 1.8 to 0.45 mM. Loratadine also inhibited the Mn2+ influx into these cells, thus reflecting the Ca2+ influx.

Substance Class	Chemical Created by `admin` on `Fri Dec 16 17:25:11 UTC 2022` Edited by `admin` on `Fri Dec 16 17:25:11 UTC 2022`
Record UNII	7AJO3BO7QN
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LORATADINE

Official Name

English

SCH-29851

Code

English

Loratadine [WHO-DD]

Common Name

English

1-PIPERIDINECARBOXYLIC ACID, 4-(8-CHLORO-5,6-DIHYDRO-11H-BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDIN-11-YLIDENE)-, ETHYL ESTER

Common Name

English

LORATADINE [MART.]

Common Name

English

LORATADINE [USP MONOGRAPH]

Common Name

English

LORATADINE [EP MONOGRAPH]

Common Name

English

LORATADINE [HSDB]

Common Name

English

LORATADINE [MI]

Common Name

English

LORATADINE COMPONENT OF CLARITIN-D

Common Name

English

BAY76-2211

Code

English

LORATADINE [USP-RS]

Common Name

English

SCH 29851

Code

English

LORATADINE [USAN]

Common Name

English

ALAVERT

Brand Name

English

CLARITIN-D COMPONENT LORATADINE

Common Name

English

loratadine [INN]

Common Name

English

NSC-758628

Code

English

LORATADINE [ORANGE BOOK]

Common Name

English

LORATADINE [VANDF]

Common Name

English

LORATADINE [JAN]

Common Name

English

CLARITIN

Brand Name

English

LORATADINE [EP IMPURITY]

Common Name

English

Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinecarboxylate

Systematic Name

English

Classification Tree Code System Code

WHO-ATC

R06AX13